Keros Therapeutics (KROS) Misses Q4 EPS by 134c

Keros Therapeutics (NASDAQ: KROS) reported Q4 EPS of ($1.34). Revenue for the quarter came in at $140 thousand.

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• UBS says bull market has further to run
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions